Global Health Innovation Act of 2015by Representative Albio Sires
Posted on 2015-12-16
SIRES. Mr. Speaker, I yield myself such time as I may consume. I
rise in support of this measure.
I want to start by thanking Chairman Royce and Ranking Member Engel for their work on global health and their efforts to bring this bill to the floor.
I would also like to thank the many Members who have cosponsored this bill, especially Congressman Mario Diaz-Balart, who has gracefully acted as the Republican lead.
Additionally, I would like to thank the staffers who worked diligently to bring H.R. 2241 to the floor for a vote.
Infectious diseases and other health conditions still claim the lives of nearly 9 million people each year. Emerging health threats, such as drug resistance, pose a serious threat to human health across the globe.
New vaccines, drugs, tests, and other health tools are desperately needed. Progress cannot be made without a sustained investment in research and development.
U.S. investments in global health research are central components of U.S.
[[Page H9349]] foreign policy to increase national security, strengthen U.S. relations around the world, and reduce infectious diseases.
The U.S. has a legacy of leadership in global health research through agencies like USAID. That is why I was proud to introduce H.R. 2241, the Global Health Innovation Act. This will provide the oversight needed to gain a clearer picture of USAID's global health research and development.
Over the years, research and development projects have greatly expanded at the USAID, searching for advancements toward an HIV- and AIDS-free generation and preventable maternal and childhood deaths, and preventable infectious diseases.
This legislation is an effort to keep up with the scope of USAID's expanded efforts and ensure their research and development activities reflect their goals and priorities. This report asks them to provide clarity on their goals and metrics to better understand their work.
H.R. 2241 directs the USAID administrator to report annually to Congress on the development and use of global health innovations in USAID programs, projects, and activities. The report must also include how the Agency measures progress, investments, and developments toward their health-related goals.
I urge my colleagues to vote in support of H.R. 2241 to allow Congress to exercise its oversight powers and ensure USAID's research and development efforts reflect their priorities.
Mr. Speaker, I thank Chairman Royce and Ranking Member Engel once again. I urge my colleagues to support H.R. 2241.
I yield back the balance of my time.